Dermatopharmacokinetic Trial of LEO 90100 Foam

Dermatopharmacokinetic Trial of LEO 90100 Foam

This is a phase 1, single centre trial in Japanese healthy male subjects comparing the amount of active ingredients of LEO 90100 foam and Dovobet® ointment in the stratum corneum.

Inclusion Criteria:

• Healthy Japanese male subjects, aged 20 to 40 years inclusive

Exclusion Criteria:

• Body Mass Index outside the range 18-25 kg/m²
• Use of any medication (systemic or topical) within 2 weeks of Day 1.